Journal of Clinical & Experimental Pharmacology

Yılmaz K

Publications

• Research Article
  Synergistic Anti-proliferative Effects of Cucurbitacin I and Irinotecan on Human Colorectal Cancer Cell Lines
  Author(s): Eyol E, Tanrıverdi Z, Karakuş F, Yılmaz K and Ünüvar SEyol E, Tanrıverdi Z, Karakuş F, Yılmaz K and Ünüvar S
  
  Colorectal cancer is the third most common cancer in men and the second in women worldwide. Treatments used for colorectal cancer include some combinations of chemotherapy, radiation therapy, surgery and targeted therapy to increase survival rates of cancer patients and decrease mortality caused by colorectal cancer. One of the many common chemotherapy drugs used in metastatic and recurrent colorectal cancer is the topoisomerase I inhibitor irinotecan. Combination of chemotherapy drugs is a common practice in the treatment of cancer. This study investigates the synergistic anti-proliferative effects of irinotecan with cucurbitacin I. The combination of antiproliferative agents can potentiate the therapeutic effects, reduce the dose, and consequently, the toxicity, and minimize or delay cases of drug resistance. Cucurbitacin I is a selective Janus kinase (JAK2)/Signal Transducers and A.. View More»
  DOI: 10.4172/2161-1459.1000219

  Abstract PDF